6-(4-chloromethylphenyl)phenanthridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-(4-chloromethylphenyl)phenanthridine
• 英文别名: 6-(4-Chloromethyl-phenyl)-phenanthridine；6-[4-(chloromethyl)phenyl]phenanthridine
• 化学式: C₂₀H₁₄ClN
• 分子量: 303.791
• InChiKey: GLWGBFXFXANWBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-(4-chloromethylphenyl)phenanthridine 在 sodium sulfite 作用下， 以 甲醇 、 水 为溶剂， 反应 11.0h， 以1 g的产率得到(4-(phenanthridin-6-yl)phenyl)methanesulfonate sodium salt
  参考文献：
  名称：

  [EN] NEW BIS-IRIDIUM-COMPLEXES FOR MANUFACTURING OF ECL-LABELS
  [FR] NOUVEAUX COMPLEXES DE BIS-IRIDIUM POUR PRÉPARER DES MARQUEURS POUR ÉLECTROCHIMILUMINESCENCE (ECL)

  摘要：

  本发明涉及新型基于双铱的Ir(III)配合物，利用这些配合物制造的标记以及生产这些配合物的方法。

  公开号：

  WO2014019710A1
• 作为产物：
  描述：

  4-氯甲基苯甲酰氯 在 三氯氧磷 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 36.0h， 生成 6-(4-chloromethylphenyl)phenanthridine
  参考文献：
  名称：

  NEW BIS-IRIDIUM-COMPLEXES FOR MANUFACTURING OF ECL-LABELS

  摘要：

  本发明涉及新型基于双铱的Ir(III)配合物，使用这些配合物制造的标签以及生产这些配合物的方法。

  公开号：

  US20150148536A1

文献信息

• Bis-iridium-complexes for manufacturing of ECL-labels
  申请人：Roche Diagnostics Operations, Inc.

  公开号：US10227366B2

  公开（公告）日：2019-03-12

  The present invention relates to novel bis-iridium-based Ir(III) complexes, labels manufactured using these complexes and a method for producing such complexes.

  本发明涉及新型双铱基 Ir(III)络合物、使用这些络合物制造的标签以及生产这些络合物的方法。
• WO2020050729A5
  申请人：——

  公开号：WO2020050729A5

  公开（公告）日：2022-06-23
• Physico-Chemical Properties of 5′-Polyarene Tethered DNA-Conjugates, and Their Duplexes with Complementary RNA
  作者：Nitin Puri、Jyoti Chattopadhyaya

  DOI：10.1080/07328319908044641

  日期：1999.11

  Fluorophores 1-13 when covalently linked to the 5'-terminus of 9-mer ssDNA (as in ssDNA-conjugates 16-28) enhance the stablity of the duplexes with both RNA (29) and DNA (30) targets compared to the natural counterparts, which, for the first time, demonstrated the effect of the bulk and the x-electron density of various 5'-tethered fluorophores on the heteroduplex stability. It has been found that decreasing the pi-electron density of the fluorophore induces a more favourable pi-pi interaction with the adjacent nucleobase, leading to higher duplex stability. Increasing the surface-area of 5'-stacked fluorophore only increases the thermal stability of the duplex, if it leads to an increase in the area of pi-overlap with the adjacent nucleobase. The fluorescence characteristics show that the tethered-fluorophores stack to the exterior of the terminal nucleobase pair, except for 5'-tethered-alpha-Napthalene (10), which shows dramatic enhancement in fluorescence as normally observed for the minor groove binders. CD data shows that tethering the DNA with different fluorophores at the 5'-end did not make any gross changes in the helical structure of the duplexes of DNA-conjugates with RNA and DNA targets compared to the natural counterparts. It has emerged that the 5'-tethered fluorophores assist in pre-organising the ssDNA-conjugates into a helical conformation more effectively by a stronger fluorophore-nucleobase stacking than in the native ssDNA. All DNA-conjugates tested assisted in cleavage of the complementary RNA strand by RNase H. The RNase H activation by 5'-conjugated DNA-RNA duplex decreased with the decrease of their thermal stabilities, and as they deviated from the structure of the corresponding native DNA-RNA duplex. It has been also found that both native and conjugated DNA-DNA duplexes can indeed block the RNase H activity, thereby reducing the effect of a potential antisense agent. This implies that the palindromic as well hairpin-forming sequences of antisense DNA should be avoided.
• A RADIOLABELLED COMPOUND OF QUATERNARY AMMONIUM SALT OF A POLYCYCLIC AROMATIC AMINE, THE USE OF THE RADIOLABELLED COMPOUND IN A DIAGNOSTIC METHOD OF POSITRON EMISSION TOMOGRAPHY, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE RADIOLABELLED COMPOUND OF QUATERNARY AMMONIUM SALT OF A POLYCYCLIC AROMATIC AMINE
  申请人：Synektik S.A.

  公开号：EP3814325A1

  公开（公告）日：2021-05-05
• RADIOLABELLED COMPOUND OF A QUATERNARY AMMONIUM SALT OF A POLYCYCLIC AROMATIC AMINE AND METHODS OF MANUFACTURING AND DIAGNOSTIC USE THEREOF
  申请人：SYNEKTIK S.A.

  公开号：US20210338847A1

  公开（公告）日：2021-11-04

  The disclosure relates to a radioisotope-labelled compound having a structure according to formula I, wherein a wavy line indicates a single bond between a non-nodal carbon atom of a polycyclic aromatic system and an R 1 substituent selected from a hydrogen; a halogen; a hydroxy; a protected hydroxy; a C 1-4 alkoxy; a nitro group; an amino group; an amino group having 1 hydrogen replaced with a C 1 -C 6 alkyl group; an amino group having 2 hydrogens replaced with a C 1 -C 6 alkyl group; an amino group having 2 hydrogen atoms replaced with C 2-5 alkylene to form a heterocyclic ring; a chain C 1-6 carbon group; a chain C 1-6 carbon group having a substituent selected from a halogen, carboxyl, a formyl, and a C 1-4 alkanesulfonic; a phenyl group; a phenyl group having 1-5 substituents independently selected from halogens, a chain C 1-6 carbon, a halogenated chain C 1-6 carbon substituent, a hydroxy, a protected hydroxy, a C 1-4 alkoxy, and an amino group having 1-2 atoms of hydrogen replaced with C 1-6 alkyl; wherein R 2 is a chain aliphatic substituent having: a total of 1-16 carbon atoms, an atom of 18 F fluorine radioisotope replacing a hydrogen atom at one of the carbon atoms, and a —CH 2 fragment as a terminal member of a chain, wherein the chain connects to one of a hydrogen, a phenyl group, and a phenyl group having 1-3 substituents selected from halogens and C 1-6 alkyl, and wherein if the chain contains at least 2 carbon atoms and there is a bivalent link between the chain carbon atoms, then the bivalent link is selected from the group consisting of an oxygen atom —O—, a sulfur atom —S—, and a C 3-6 cycloalkylene; wherein R 3 and R 4 are combined to form a bivalent butadienyl-1,3 substituent whose terminal carbon atoms are linked to adjacent non-nodal carbon atoms of a B ring to form an aromatic C ring fused with an A and B ring system, having R 1 substituents at non-nodal carbon atoms; wherein n is an integer of 9; wherein X − is a pharmaceutically acceptable counter ion selected from: an anion of a mono-basic inorganic acid, a mononegative anion of a multi-basic inorganic acid, an anion of an alkane carboxylic acid, an anion of an aliphatic sulfonic acid, an anion of an aromatic sulfonic acid, an anion of an acidic amino acid, a hydrate thereof, and a solvate thereof.